Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC

Phase 3 REZILIENT 3 trial reports a six-month improvement in median progression-free survival and higher response rates with the combination SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free...